SkyePharma files Flutiform for asthma in the US
This article was originally published in Scrip
Executive Summary
SkyePharma has filed an NDA in the US for its lead candidate Flutiform (fluticasone propionate plus formoterol fumarate), for the maintenance treatment of asthma in patients aged over 12 years.